PeptidePlaza
The Free Peptide Reference

Insulin Aspart Protamine Recombinant

From PeptidePlaza, the free peptide reference · Entry #1089 · Metabolic · Sources fetched 2026-09-11 · Editorial standards

Insulin Aspart Protamine Recombinant (also known as Insulin-aspart, Aspart, Aspart insulin, Insulin B28asp) is a metabolic research peptide. Insulin Aspart Protamine Recombinant is an insulin receptor agonist, FDA-approved for managing diabetes mellitus.

Insulin Aspart Protamine Recombinant is a modified form of human insulin, classified as an insulin receptor agonist. It functions by binding to insulin receptors, mimicking the action of endogenous insulin to regulate glucose metabolism. Approved by the FDA in 2001, it is used in the management of diabetes mellitus. Research on Insulin Aspart Protamine Recombinant includes reviews on insulin analogues and insulin therapy, as well as studies on its structural properties in formulations and cases of allergy to insulin.

1 Mechanism of action

Insulin receptor agonist (agonist)

Primary targets: Insulin receptor

2 Reported effects

Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.

2.1 Indicated / studied for

  • Diabetes mellitus

3 Chemical and physical properties

CAS number116094-23-6
Molar mass5832 g/mol
Purity (typical)Not independently verified
Storage−20 °C, lyophilised powder, desiccated
SolubilitySterile water / bacteriostatic water
Receptors / targetsInsulin receptor

4 Research studies (6)

  1. Update on insulin analogues
    Drug and therapeutics bulletin (2004) · Review
  2. Two Cases of Allergy to Insulin in Gestational Diabetes
    Endocrinology and metabolism (Seoul, Korea) (2015)
  3. Narrative review: a rational approach to starting insulin therapy
    Annals of internal medicine (2006) · Review
  4. Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised?
    Drugs (2007) · Review
  5. Insights into the Structural Coexistence of Hexameric States in Microcrystalline Insulin Formulations in the Solid State
    Molecular pharmaceutics (2026)
  6. [A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus]
    Yakushigaku zasshi (2003)

5 Safety and risk profile

5.1 Regulatory status

Insulin Aspart Protamine Recombinant is currently classified as FDA approved. Approval applies to specific clinical indications and dosing; research-grade material is not the approved product.

Safety data disclaimer. Safety assessments are based on published literature and are for educational reference only. Clinical evidence varies significantly between peptides. Always consult primary research and current regulatory guidance.

6 Frequently asked questions

What is Insulin Aspart Protamine Recombinant used for?
Insulin Aspart Protamine Recombinant is used for the management of diabetes mellitus. It is an FDA-approved medication that helps regulate blood glucose levels in individuals with diabetes.
How does Insulin Aspart Protamine Recombinant work?
Insulin Aspart Protamine Recombinant works as an insulin receptor agonist. It binds to insulin receptors on cells, which initiates a cascade of events that leads to the uptake of glucose from the blood into cells, thereby lowering blood glucose levels.
Is Insulin Aspart Protamine Recombinant FDA approved?
Yes, Insulin Aspart Protamine Recombinant is FDA approved. It received its first approval in 2001 for its use in the treatment of diabetes mellitus.
What is Insulin Aspart Protamine Recombinant?
Insulin Aspart Protamine Recombinant is a modified form of human insulin. It is an insulin receptor agonist, meaning it mimics the action of natural insulin in the body to help control blood sugar.

7 References

  1. Insulin Aspart Protamine Recombinant — compound summary PubChem. View source
  2. Insulin Aspart Protamine Recombinant — molecule record ChEMBL. View source
  3. Insulin Aspart Protamine Recombinant — published literature (6 records) PubMed. View source

Related compounds

Entries that share a target, a mechanism, or a research area with Insulin Aspart Protamine Recombinant.

Insulin Glargineapproved

Also targets Insulin receptor

Insulin Glargine is a long-acting human insulin analog and an insulin receptor agonist, FDA-approved to improve glycemic control in patients with type 1 and type 2 diabetes mellitus.

Insulin Aspartapproved

Also targets Insulin receptor

Insulin Aspart is a rapid-acting human insulin analog that functions as an insulin receptor agonist, primarily used to improve glycemic control in patients with diabetes mellitus.

Insulin Lisproapproved

Also targets Insulin receptor

Insulin Lispro, also known as Lyumjev, is a rapid-acting human insulin analog that acts as an insulin receptor agonist.

Insulin Degludecapproved

Also targets Insulin receptor

Insulin Degludec is a long-acting human insulin analog and an insulin receptor agonist, FDA-approved for improving glycemic control in adults with type 2 diabetes mellitus.

Insulin Detemirapproved

Also targets Insulin receptor

Insulin Detemir, also known as Levemir, is a long-acting human insulin analog and an insulin receptor agonist used to improve glycemic control in patients with diabetes mellitus.

Insulin Zincapproved

Also targets Insulin receptor

Insulin Zinc is an insulin receptor agonist that is FDA-approved for medical use.

8 See also

For research reference only. Not medical advice. Peptides may be regulated or restricted in your jurisdiction. Entry validated by the PeptidePlaza Biomedical Research Desk; see editorial standards.